Table 1.
Safety/tolerability of salsalate and young plasma compared to historical placebo cohort
| Historical Placebo, N (% cohort) | Salsalate, N (% cohort) | YP, N (% cohort) | |
|---|---|---|---|
| Patients with at least one event | 148 (94.9) | 9 (90) | 5 (100) |
| All AEs by system organ class | |||
| Cardiovascular (palpitations, QRS complex widening) | 10 (6.4) | 1 (10 | 1 (20) |
| Dermatologic (flushing, itching, rash) | 21 (13.5) | 1 (10) | 5 (40) |
| Eye/vision (irritation, worsening vision) | 20 (12.8) | 2 (20) | 0 |
| Gastrointestinal (constipation, dyspepsia) | 48 (30.8) | 3 (30) | 0 |
| Infections (skin infection, UTI) | 68 (43.6) | 1 (10) | 1 (20) |
| Injuries (falls, lacerations, contusions) | 86 (55) | 11 (50) | 10 (60) |
| Musculoskeletal (fracture, joint/muscle pain) | 43 (27.6) | 12 (60) | 3 (40) |
| Nervous system (dizziness, fatigue, headache) | 62 (39.7) | 2 (20) | 4 (60) |
| Respiratory (cough, congestion, shortness of breath, PE) | 61 (39.1) | 5 (30) | 1 (20) |
| Serious AEs | 54 | 1 (DVT/PE) | 0 |